Stay Positive


"In the midst of winter I finally learned that there was in me an invincible summer."

- Alert Camus








Friday, November 24, 2017

Strauss -- Der Rosenkavalier, Final Trio -- K. Battle, F. von Stade, R. Fleming


This is a clip from the 1992 New Year's Eve Concert, Richard Strauß Gala in Berlin, Germany.
Wonderful performance by three gems of the opera world: 

Sophie: Kathleen Battle 

Octavian: Frederica von Stade 

Marschallin: Renee Fleming 

Recorded on December 31, 1992 in Berlin. 
Featuring:
Andreas Schmidt
Claudio Abbado
Berliner Philharmoniker




Thursday, November 23, 2017

Relaxing Music: Elina Garanca - Bel Canto



Elina Garanca - Bel Canto / 2009

 






Published on Jan 15, 2016
Meditation, Elina Garanca
http://www.deezer.com/album/8448975 
 01. Lucrezia Borgia Act 2 - Il segreto per esser felici 
02. L'assedio di Calais Act 1 - Al mio core 
03. Roberto Devereux Act 1 - All afflitto e dolce il pianto 
04. Dom Sebastien Roi de Portugal Act 2 - Que faire Sol adore de la patrie 
05. Adelson e Salvini Act 1 - Dopo l'oscuro nembo 
06. Maria Stuarda Act 1 - Si vuol di Francia il Rege 
07. Maria Stuarda Act 1 - Ah quando all ara scorgemi 
08. Maria Stuarda Act 1 - In tal giorno di contento 
09. Maria Stuarda Act 1 - Ah dal ciel discenda un raggio 
10. Tancredi Act 1 - Andante 
11. Tancredi Act 1 - O patria dolce e ingrata patria 
12. Tancredi Act 1 - Di tanti palpiti 
13. Maometto II Act 2 - Terzetto In questi estremi istanti 
14. I Capuleti e i Montecchi Act 1 - Lieto del dolce incarco 
15. I Capuleti e i Montecchi Act 1 - Ascolta se Romeo t uccise 
16. I Capuleti e i Montecchi Act 1 - Riedi al campo 
17. I Capuleti e i Montecchi Act 1 - La tremenda ultrice spada 
18. L assedio di Calais Act 2 - Io l udia





Friday, November 17, 2017

Does Parasitic Skin Disease - Morgellons - Even Exist? | NBC Left Field

Sound familiar? Rare conditions often go unrecognized by the medical establishment.



Thousands claim to have Morgellons, a condition that allegedly causes fibers to grow out of the skin.



A small team of researchers have linked it to Lyme disease, but here’s the thing: according to the Centers for Disease Control and Prevention and the majority of doctors, Morgellons does not exist, and there is “no common underlying medical condition” that explains reported symptoms.



Most doctors believe that Morgellons patients are actually suffering from a delusional disorder — and Morgellons is not recognized in diagnostic manuals.




Monday, November 13, 2017

How bacteria in the gut influence neurodegenerative disorders


Our last press conference of the day begins. Scientists will discuss how bacteria in the gut influence neurodegenerative disorders like and
Tracy Bale of moderates.


On her results: "[They] suggest that APOE alleles may differentially affect the gut microbiome...[contributing] to the actions of APOE in modulating Alzheimer’s disease risk."

  







Friday, November 3, 2017

Stem Cell and other potential treatments

cause remission of - improve quality of life. we need patient choice and approval. so we can live better


MS & ME Internet Radio : MS, The Edge Live now! Listen here: -



   




Swiss Biotech and French Pharma Reverse Damage in Multiple Sclerosis

From The Clinic
Evelyn Warner on 01/11/2017



A candidate multiple sclerosis treatment from GeNeuro and its partner Servier showed some remyelination in a post hoc analysis of Phase IIb data.
GeNeuro’s stock rose by 30% on Monday following an announcement of promising results from its relapsing-remitting multiple sclerosis drug, GNbAC1. After six months, the highest dose demonstrated an anti-inflammatory effect and seemed to stimulate remyelination.
“When we released topline results after 24 weeks in August, we communicated that we had missed the primary endpoint: the cumulative number of gadolinium-enhancing lesions,” Jesús Martin-Garcia, CEO of GeNeuro, told us. “At the time, we formulated a hypothesis that this could be led by the late onset of action.”
GNbAC1 is a monoclonal antibody that targets a pathogenic retroviral envelope protein that has been found in all types and stages of multiple sclerosis. By neutralizing this protein, they reduced lesions and inflammation in the brain.  As Martin-Garcia described it, “We’re not directly impacting the immune system, like immunomodulating or immunosuppressive drugs. We’re neutralizing a pathogenic protein, so it may take longer for the effect to be seen on inflammatory markers.”

There are a number of companies working on a treatment for multiple sclerosis. Though Teva and Active Biotech recently faced a late-stage failure, Biogen has stepped up to the plate and recently recruited Swiss genomics outfit BC platforms.
So far, GeNeuro’s approach verges on unique: “There’s a tremendous amount of literature coming up today about pathogenic HERV proteins from leading research centers,” said Martin-Garcia. “But in the clinic, we’re really the only company.” Some academic centers are trying to treat the disease with antiretrovirals, which is the same concept but different tool.
So with the positive news in hand, what’s next for GeNeuro? “We have encouraging data here. Hopefully, we can open new avenues by neutralizing causal factors of these diseases, to slow down or stop their progression,” said Martin-Garcia. “Now we have to confirm how GNbAC1 performs after 48 weeks.” 
Curious? Hear more from the CFO of GeNeuro in our video interview.

Co-authored by Clara Rodríguez-Fernández

Images via Designua, ustas7777777 / shutterstock.com